ClinicalTrials.gg
RecruitingNCT06087653Updated Aug 24, 2026

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

A Phase 1/2 interventional study of Lenalidomide and Lenalidomide 25 MG Oral Capsule in Multiple Myeloma, sponsored by Starton Therapeutics, Inc. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Starton Therapeutics, Inc · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Planned enrollment
182nd of 249
24 · median 50
Started
2023
with 8 others
Phase 1/2
37 of 249
6 open now
Primary completion
2027-05
later than 35 of 69 live
Registered
231st of 249
by date

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 182nd largest by planned enrollment, is one of 9 that started in 2023, is one of 37 in phase 1/2, reaches primary completion later than 35 of the 69 other live ones, and was the 231st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI).

Secondary Objectives

    • To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations.
    • Evaluate changes in efficacy indicators including objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR).

Exploratory Objective

  • To assess the impact of STAR-LLD on patient reported symptoms and outcomes. Primary Endpoints
  • The grade, frequency, and relationship of treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESIs): (gastrointestinal [GI] toxicity, fatigue, hematologic toxicity, rash (non-infusion site).
  • The observation of dose-limiting toxicities (DLTs) of STAR-LLD during Cycle 1. Secondary Endpoints

    •• Blood concentrations of lenalidomide at on Day 1 and at steady state.

  • Changes in biomarkers during treatment.
  • Rate of complete response, very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease.
  • Determination of ORR, PFS, and DOR
03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years at the time of .
  2. stem cell transplant (ASCT) ineligible.
  3. SARS -CoV2 virus (COVID)-19 negative.
  4. A prior diagnosis of MM as defined by International Myeloma Working Group (IMWG) criteria (Appendix 7).
  5. Documented following therapy defined as:

    • Serum monoclonal protein ≥1.0 g/dL by protein electrophoresis.
    • ≥200 mg/24 hours of monoclonal protein in the urine on 24-hour electrophoresis.
    • Serum free light chain (SFLC) ≥10 mg/dL AND abnormal serum kappa to lambda free light chain (FLC) ratio.
  6. Intended to be treated in 2nd line or greater with lenalidomide, dexamethasone, and a PI.
  7. Proteasome inhibitor sensitive defined as progression free for > 6 months from cessation of PI or never received a prior PI.
  8. Progression per IMWG criteria on the most recent line of therapy.
  9. (ECOG-Appendix 1) performance status ≤2 (patients with a performance status of 3 based solely on bone pain secondary to MM may be eligible following consultation and approval by the Medical Monitor).
  10. Willing to comply with the protocol defined Lenalidomide Pregnancy Risk Minimization Plan for the prevention of pregnancy (Appendix 5). Females of (FCBP) must have a medically supervised negative serum or urine pregnancy test 4-14 days prior to planned start of treatment and again 24 hours prior to initiation of study medication. All FCBP must agree to either commit to continued abstinence from sexual intercourse or begin TWO acceptable methods of AT THE SAME TIME, at least 28 days before receiving the first dose of STAR-LLD. FCBP must also agree to ongoing pregnancy testing. Males must agree to use a latex or synthetic condom during sexual contact with a FCBP from the time of starting study treatment through 28 days after the last dose, even if they have had a vasectomy.
  11. Able to take anti-thrombotic prophylaxis.
  12. The following laboratory results must be met during screening:

    • ≥1,000 cells/mm3 (1.0 x 109/L).
    • count ≥75,000 cells/mm3 (75 x 109/L).
    • ≥8.0 g/dL (red blood cell (RBC) transfusions are permitted prior to initiation of study drug if hemoglobin is stable for 72 hours).
    • Total ≤1.5 x (ULN), or patient diagnosed with Gilberts syndrome with a total bilirubin \<5.0 x ULN that has been reviewed and approved by the Medical Monitor.
    • (AST) and alanine aminotransferase (ALT) ≤3.0 x ULN.
    • Calculated ≥60 mL/min. Appendix 4
    • Negative pregnancy test for FCBP (must be obtained within 4-14 days before the initiation of study drug.
  13. The following criteria must be met within 72 hours prior to first administration of continuous infusion STAR-LLD:

    • ANC ≥1,000 cells/mm3 (1.0 x 109/L).
    • Platelet count ≥75,000 cells/mm3 (75 x 109/L).
    • Hemoglobin ≥8.0 g/dL (RBC transfusions are permitted prior to initiation of study drug if hemoglobin is stable for 72 hours).
    • Calculated creatinine clearance ≥60 mL/min. Appendix 4
    • Negative pregnancy test for FCBP (must be obtained within 24 hours of first dose of study drug).
  14. Able and willing to receive percutaneous ambulatory therapy.
  15. Has an in-home care partner willing to receive training from a nurse for assistance with pump management.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding.
  2. Received an .
  3. Venous thromboembolism within 12 months of starting treatment on study.
  4. Patients with active or C or (HIV) positive and on active therapy for those viral illnesses.
  5. Currently taking any therapy for the treatment of MM. A 28-day prior to Cycle 1 Day 1 is required for any previous investigational therapy.
  6. Received a prior treatment line containing lenalidomide and failed to achieve an objective response (CR, VGPR or PR).
  7. Discontinued a due to intolerability to lenalidomide.
  8. Concomitant use of strong inducers (see https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-3).
  9. Concurrent amyloidosis or plasma cell leukemia or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes).
  10. Known active infection requiring systemic anti-infective treatment (prophylactic treatment is permitted).
  11. Prior within the previous 3 years, other than previously treated squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix or breast or another malignancy that is considered cured with minimal risk of recurrence (e.g., very low and low risk prostate cancer in active surveillance).
  12. Prior major surgical procedure or radiation therapy within 4 weeks of the initiation of STAR-LLD (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of STAR-LLD).
  13. Any other condition that precludes adequate understanding, cooperation, and compliance with study procedures or any condition that could pose a risk to the patient's safety, as per the Investigator's judgment.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    ARM1 - Lenalidomide 400 mcg/h

    Lenalidomide 400 mcg/hr continuously for 28 of 28-day cycle

    Drug: Lenalidomide

  • Experimental
    Arm2 - Lenalidomide 300 mcg/h

    Lenalidomide 300 mcg/hr continuously for 28 of 28-day cycle

    Drug: Lenalidomide

  • Experimental
    Arm 3 - Lenalidomide 500 mcg/h

    Lenalidomide 500 mcg/hr continuously for 28 of 28-day cycle

    Drug: Lenalidomide

  • Experimental
    Arm 4 - Lenalidomide 600 mcg/h

    Lenalidomide 600 mcg/hr continuously for 28 of 28-day cycle

    Drug: Lenalidomide

  • Active comparator
    Arm 5 - Lenalidomide oral capsule control

    Lenalidomide 25mg/d oral capsules continuously for 28 of 28-day cycle

    Drug: Lenalidomide 25 MG Oral Capsule

Interventions

  • Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone

    Also known as: bortezamib, dexamethasone

  • Oral lenalidomide for active control

06

What researchers measure

Primary outcomes

  1. Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI).

    Based on the incidence of adverse events associated with the use of the drug

    Time frame: 12 months

Secondary outcomes

  1. To assess the immunologic activity of natural killer (NK) cells and T cells for innate and humoral immunity.

    Measure changes in T cell and NK cell function/exhaustion over the study by flow cytometry

    Time frame: 12 months

  2. To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations.

    Meaured vs predicted blood concentrations of lenalidomide during the infusion and at steady state

    Time frame: 12 months

  3. To determine pharmacodynamic (PD) changes with STAR-LLD in a panel of biomarkers associated with clinical response to lenalidomide.

    Evaluate desirable changes in immune cells activity over therapy

    Time frame: 12 months

  4. Evaluate changes in efficacy indicators including objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR).

    An ORR of 60% is representative of patients being retreated with PI and Len

    Time frame: 12 months

Other outcomes

  1. Assess the DOR, PFS during treatment

    Report the deprived data for these outcomes

    Time frame: 18 months

07

Study locations

1 of 2 sites recruiting
  • Regional Oncology Center
    Wilson, North Carolina 27893, United States
    Active, not recruiting

    Not enrolling at this site.

  • Gabrail Cancer & Research Center
    Canton, Ohio 44718, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for May 2027, 43 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 43 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Oct 18, 2023
StartActual
Oct 2, 2023
Primary completionEst.
May 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06087653
Lead sponsor
Starton Therapeutics, Inc
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Oct 2, 2023
Primary completion
May 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Aug 24, 2026

Study contacts

Amy Chergey
Contact
achergey@startontx.com
949 433 6750

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion